HLA alleles and hypersensitivity to carbamazepine

Grover, Sandeep; Kukreti, Ritushree

doi:10.1097/fpc.0000000000000021

Cited by 74 publications

(23 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the association between HLA-B*15:02 and the development of carbamazepine-induced SJS was first described among Han Chinese [71]. Several other studies have provided evidence to strengthen this association, which has been found in other Asian ethnicities such as Thai, Korean, Malay, and Indian populations, but not Japanese [70]. In a European case-control study including 12 carbamazepine-induced SJS/TEN cases, however, only 4 patients (all of Asian ancestry) were HLA-B*15:02 positive [72].…”

Section: Carbamazepinementioning

confidence: 98%

“…Many HLA alleles associated with carbamazepine-induced SCAR have been identified, and the strongest associations have been reported for HLA-B*15:02 and HLA-A*31:01 [70]. Carriers of these alleles are mainly of South Asian ancestry.…”

Section: Carbamazepinementioning

confidence: 99%

“…Protective HLA alleles (such as HLA-B*40:01 and HLA-A*24:02) against the development of carbamazepine cutaneous DDAR have also been identified, particularly in Asian populations [70]. It is still unknown, however, whether these alleles exert a true protective effect or simply appear to be more frequent in the general population than in SJS/TEN cases [70,76].…”

Section: Carbamazepinementioning

confidence: 99%

“…It is still unknown, however, whether these alleles exert a true protective effect or simply appear to be more frequent in the general population than in SJS/TEN cases [70,76]. …”

Section: Carbamazepinementioning

confidence: 99%

See 3 more Smart Citations

HLA and Delayed Drug-Induced Hypersensitivity

Sousa‐Pinto¹,

Correia²,

Gomes³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Delayed drug allergy reactions (DDAR) are potentially fatal. Certain human leukocyte antigen (HLA) alleles have been associated with delayed allergy reactions following the administration of particular drugs. Examples are HLA-B*57:01 (abacavir), HLA-B*15:02/HLA-A*31:01 (carbamazepine), and HLA-B*58:01 (allopurinol). Based on the identification of these associations, it may now be possible to prevent certain allergy reactions that were, until recently, considered unpredictable. In this review, we will focus on the pharmacogenetics of the best-studied associations between specific HLA alleles and delayed allergy reactions and describe the pathogenesis models proposed so far. Finally, we will evaluate the genetic screening strategies available and discuss the clinical relevance of a better understanding of the immunogenetics and mechanisms involved in DDAR.

show abstract

Section: Carbamazepinementioning

confidence: 98%

Section: Carbamazepinementioning

confidence: 99%

Section: Carbamazepinementioning

confidence: 99%

“…It is still unknown, however, whether these alleles exert a true protective effect or simply appear to be more frequent in the general population than in SJS/TEN cases [70,76]. …”

Section: Carbamazepinementioning

confidence: 99%

See 2 more Smart Citations

HLA and Delayed Drug-Induced Hypersensitivity

Sousa‐Pinto¹,

Correia²,

Gomes³

et al. 2016

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…One meta-analysis indicated that the association of HLA-A * 3101 with CBZ-induced HSS (OR = 13.2) was stronger than with SJS/TEN (OR = 3.94) [27]. Another comprehensive meta-analysis including more studies suggested that HLA-A * 3101 was a universal risk marker, irrespective of cutaneous ADR type [SJS/TEN: p = 4.03 × 10 -6 , OR (95% CI) = 5.65 (2.70-11.78); HSS/MPE: p = 4.46 × 10 -22 , OR (95% CI) = 8.58 (5.55-13.28)] [33]. …”

Section: Pharmacogenomics Study Of Drug-induced Sjs/ten: Association mentioning

confidence: 99%

Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity

Lee

Mahasirimongkol²,

Zhang

et al. 2014

Public Health Genomics

View full text Add to dashboard Cite

Pharmacogenomics is gradually becoming more and more indispensable in modern medicine. In several cases, a pharmacogenomics test may alleviate serious drug-induced adverse reactions, if it precedes drug prescription. In this article, we provide an overview of the well-established HLA-based carbamazepine- and allopurinol-induced adverse reactions, as one of the most characteristic examples of the clinical application of pharmacogenomics, highlighting its regional impact in Southeast Asian populations in preventing adverse reactions of certain drug/allele pairs. This example provides useful insights towards evidence generation for policy implementation, including economic evaluation analysis, the implementation of pharmacogenomics testing procedures and monitoring of policy effectiveness, hence serving, per se or in the context of international collaborative efforts, as a model for similar cases in several national healthcare systems worldwide.

show abstract